stockd
PL EN
995 REPORTS
638 COMPANIES
an hour ago

RDG

READ-GENE Active
NEWCONNECT PL Biotechnologia
Follow
Latest report: Q1 2026, Published: June 17, 2026 Rating: 6.2/10
Positive

Grupa READ-GENE przeszła z okresu strat do wyraźnie rentownego kwartału — skonsolidowany zysk netto 883 tys. zł wobec straty 298 tys. zł rok wcześniej

Previous
Q4/25 → FY/25
Analysis →
Market cap
—
no data
Announcements
1
/ 30 days
Reports
3
on file
Most important announcements in the last 30 days

Announcements

5 of 20 announcements

Stockd AI rating

All
Type
Sentiment
All announcements →

Finance

BETA
5 reports

The financial chart and controls are available after signing in.

Report analyses

5 of 5

Quarterly report Q1 2026

Grupa READ-GENE przeszła z okresu strat do wyraźnie rentownego kwartału — skonsolidowany zysk netto 883 tys. zł wobec straty 298 tys. zł rok wcześniej

Positive No guidance change Rating: 6.2/10
Report published: Jun 17 Analyzed: Jun 22
Source

Quarterly report Q1 2026

Grupa READ-GENE przeszła z okresu strat do wyraźnie rentownego kwartału — skonsolidowany zysk netto 883 tys. zł wobec straty 298 tys. zł rok wcześniej

Positive No guidance change Rating: 6.2/10
Report published: Jun 17 Analyzed: Jun 22
Source

Annual report FY 2025

Spółka wraca do rentowności po stracie 2024 r. — przychody +33,8% r/r, zysk netto 645,6 tys. PLN.

Neutral No guidance change Rating: 5.3/10
Report published: Jun 01 Analyzed: Jun 22
Source

Annual report FY 2025

Spółka wraca do rentowności po stracie 2024 r. — przychody +33,8% r/r, zysk netto 645,6 tys. PLN.

Neutral No guidance change Rating: 5.3/10
Report published: Jun 01 Analyzed: Jun 22
Source

Quarterly report Q4 2025

Powrót skonsolidowanej Grupy do zysku netto (96,8 tys. zł vs -1,11 mln zł rok wcześniej) po dwóch latach strat

Positive No guidance change
Report published: Jun 01 Analyzed: Jun 22
Source

Contracts

BETA

We haven't found any contracts in this company's filings

We only detect contracts from ESPI/EBI current filings and periodic reports, checked automatically every few minutes. The company may not have reported them in a detectable way, or our parser hasn't covered them yet.

Report a missing contract

Shareholders

3 holders
As of August 16, 2026 · ≥5% shareholder roster
Shareholders ≥5%: 80.16% Free float: 19.84%
Vote control
71.79%
Majority shareholder — Gen-Pat-Med Sp. z o.o.
Gen-Pat-Med Sp. z o.o. 67.06%
7,905,875
Jan Lubiński 7.16%
843,856
Adamed Sp. z o.o. 5.94%
700,000
Free float 19.84%
—
Company data & listing Expand
Sector
Biotechnologia
Industry
Biotechnologia
Exchange
NEWCONNECT
Country
PL
Reporting currency
PLN
FY end
12-31
Standard
PSR (Polish GAAP)
ISIN
PLRADGN00014
CEO
Jan Lubiński
Authorized adviser
allStreet Spółka z ograniczoną odpowiedzialnością
Address
UL. AKACJOWA 2 71-253 SZCZECIN
Phone
(91) 433 42 56 602784784
Listed since
May 17, 2026
Market cap
—
Status
Active